Treatment
Venetoclax clinical trials
We’re tracking 281 recruiting studies that include Venetoclax, each written for real people, not researchers, below.
Recruiting studies
- NCT07117422Recruiting
Venetoclax and decitabine for untreated AML in older or frail adults
This study tests a combination of two oral and IV medicines (venetoclax and decitabine) for older adults or people who cannot receive strong chemotherapy for newly diagnosed acute myeloid leukemia (AML). The goal is to see if this gentler treatment can help control the disease with fewer side effects.
HebeiAges 65 years+ - NCT07132684RecruitingPhase 3
Comparing two chemotherapy plans for older AML patients
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
TianjinAges 55–75 - NCT07154264RecruitingPhase 2
Study of new targeted drug combo for newly diagnosed CLL/SLL
This study tests a new targeted drug (DZD8586) in combination with other therapies for people who have just been diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and have not yet received any treatment. The goal is to see if this combination works better than current standard treatments.
Hefei, AnhuiAges 18 years+ - NCT07304011RecruitingPhase 2
Olutasidenib and azacitidine for IDH1-mutated AML after venetoclax
This trial tests whether adding the targeted therapy olutasidenib to the chemotherapy drug azacitidine can help people with a certain type of AML (one with an IDH1 mutation) who have already had some treatment but still have the disease. The goal is to see if this combination can lead to a longer remission.
Sacramento, CaliforniaAges 18 years+ - NCT07283094RecruitingPhase 1
FHD-286 with decitabine and venetoclax for AML
This early-phase trial tests a new study drug called FHD-286 combined with two standard AML medicines (decitabine and venetoclax). It is for people with a high-risk type of AML that is either newly diagnosed (and you cannot have strong chemotherapy) or has come back after one prior treatment.
The Bronx, New YorkAges 18 years+ - NCT07320235RecruitingPhase 1
Combination treatment for relapsed AML
This trial tests a new combination of drugs for people whose acute myeloid leukemia (AML) has come back or not responded after at least one prior treatment, and who have no other standard options. The goal is to see if adding imetelstat to other therapies can help.
New York, New YorkAges 18 years+ - NCT07670130Recruiting
Venetoclax TDM in Newly Diagnosed AML: Response and Outlook
This study looks at how the drug venetoclax works in people newly diagnosed with acute myeloid leukemia (AML). It helps doctors understand the right dose for better results.
SuzhouAges 16 years+ - NCT02781883RecruitingPhase 2
Test drug BP1001 with venetoclax and decitabine for AML
This Phase 2 study tests BP1001 added to venetoclax plus decitabine in adults with acute myeloid leukemia (AML). It aims to improve leukemia control in people who may not be able to get standard intensive chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT03342144Recruiting
Venetoclax for chronic lymphocytic leukemia in real-world care
This study looks at how well venetoclax works and how it’s used when people with chronic lymphocytic leukemia (CLL) start the medication in usual, real-life care. It may help doctors better understand what to expect outside of strict study settings.
Sankt Pölten, Lower AustriaAges 18 years+ - NCT00501826RecruitingPhase 2
Check nelarabine plus chemotherapy for T-cell blood cancers
This trial tests a combination of chemotherapy with nelarabine in people with T-cell acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma. It may help by improving remission in newly diagnosed or certain previously treated patients whose disease did not respond after one initial treatment.
Houston, TexasAges Any age - NCT07425782RecruitingPhase 2
Venetoclax and azacitidine as consolidation for high-risk AML
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
Suzhou, JiangsuAges 18 years+ - NCT07471841RecruitingPhase 2
Olutasidenib for IDH1-mutated AML after venetoclax
This trial tests the drug olutasidenib for people with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. It is for patients who have already received the drug venetoclax and have an IDH1 mutation in their leukemia cells.
Winston-Salem, North CarolinaAges 18 years+ - NCT07512700RecruitingPhase 2
New drug combination versus standard therapy for acute monocytic leukemia
This study tests whether a newer drug called venetoclax, combined with a chemotherapy regimen called CACAG, works better than the standard "3+7" chemotherapy for treating acute monocytic leukemia (a blood cancer). The goal is to help patients achieve remission and improve survival.
BeijingAges 14–60 - NCT07514832RecruitingPhase 2
New chemotherapy combination for untreated acute myeloid leukemia
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
BeijingAges 18–70 - NCT07563179RecruitingPhase 2
Bugitinib with Venetoclax and Cytarabine for Relapsed AML
This trial tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) for patients with acute myeloid leukemia (AML) that has returned or didn't respond to prior treatments. The goal is to see if this combination can help patients achieve remission and improve survival.
Shenzhen, GuangdongAges 18–70 - NCT07602088Recruiting
Real-world Study of Two Cancer Drugs for Chronic Lymphocytic Leukemia
This study follows patients with chronic lymphocytic leukemia (CLL)—a blood cancer—who are starting treatment with two drugs called ibrutinib and venetoclax together for a set period of time. Researchers want to understand how well this treatment works and how it affects patients' daily lives in real-world settings, rather than in a controlled lab environment.
BucharestAges 18 years+ - NCT07672262RecruitingPhase 2
VA maintenance before transplant for intermediate-risk AML
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
Suzhou, JiangsuAges 18 years+
Common questions
- Are there clinical trials studying Venetoclax?
- Yes. Clin2 currently lists 281 recruiting studies that include Venetoclax, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Venetoclax trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Venetoclax an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Venetoclax or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.